Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.54 |
| ▸ | PTPRC | P08575 | 3/20 | 0.50 |
| ▸ | S100A4 | P26447 | 2/20 | 0.50 |
| ▸ | KCNJ1 | P48048 | 1/20 | 0.50 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.50 |
| ▸ | BCHE | P06276 | 1/20 | 0.49 |
| ▸ | ACHE | P22303 | 1/20 | 0.49 |
| ▸ | CES1 | P23141 | 1/20 | 0.49 |
| ▸ | MAOA | P21397 | 4/20 | 0.48 |
| ▸ | MAOB | P27338 | 3/20 | 0.48 |
| ▸ | CA1 | P00915 | 2/20 | 0.46 |
| ▸ | CA2 | P00918 | 2/20 | 0.46 |
| ▸ | CA9 | Q16790 | 2/20 | 0.46 |
| ▸ | CA12 | O43570 | 1/20 | 0.46 |
| ▸ | TDP2 | O95551 | 1/20 | 0.46 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.46 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.46 |
| ▸ | LMNA | P02545 | 3/20 | 0.45 |
| ▸ | MEN1 | O00255 | 2/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30677628 | 1.00 | ALDH1A1 (0.54) | ALDH1A1PTPRCS100A4KCNJ1KCNH2 | |
| SCHEMBL3624177 | 0.86 | KCNJ1 (0.60) | ALDH1A1PTPRCS100A4KCNJ1KCNH2 | |
| SCHEMBL12236614 | 0.83 | ALDH1A1 (0.51) | ALDH1A1PTPRCS100A4BCHEACHE | |
| SCHEMBL31504012 | 0.81 | CA1 (0.45) | ALDH1A1PTPRCS100A4BCHEACHE | |
| SCHEMBL10415981 | 0.79 | ALDH1A1 (0.61) | ALDH1A1PTPRCS100A4BCHEACHE | |
| SCHEMBL6747753 | 0.78 | PTPRC (0.49) | ALDH1A1PTPRCS100A4BCHEACHE | |
| SCHEMBL1308432 | 0.77 | ALDH1A1 (0.60) | ALDH1A1PTPRCS100A4BCHEACHE | |
| SCHEMBL13743207 | 0.75 | ALDH1A1 (0.47) | ALDH1A1PTPRCS100A4KCNJ1KCNH2 | |
| SCHEMBL5035485 | 0.73 | ALDH1A1 (0.51) | ALDH1A1PTPRCS100A4KCNJ1KCNH2 | |
| SCHEMBL27357554 | 0.73 | ALDH1A1 (0.51) | ALDH1A1PTPRCS100A4BCHEACHE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 225 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023027630-A9 | A FLOW REACTOR, METHODS OF FABRICATION AND REACTIONS THEREOF | NATIONAL UNIVERSITY OF SINGAPORE (SG) | 2023-07-27 | — | — | WO | claimed |
| WO-2023027630-A2 | A FLOW REACTOR, METHODS OF FABRICATION AND REACTIONS THEREOF | NATIONAL UNIVERSITY OF SINGAPORE (SG) | 2023-03-02 | — | — | WO | claimed |
| CN-101580507-B | Novel antitumor compound and preparation method and application thereof | UNIV EAST CHINA SCIENCE & TECH | 2011-08-03 | — | — | CN | claimed |
| CN-101781304-A | Tetrahydroisoquinoline compound and preparation method and application thereof | UNIV EAST CHINA SCIENCE & TECH | 2010-07-21 | — | — | CN | claimed |
| US-7732534-B2 | Polymers functionalized with nitro compounds | BRIDGESTONE CORPORATION (JP) | 2010-06-08 | — | — | US | claimed |
| CN-101580507-A | Novel antitumor compound and preparation method and application thereof | UNIV EAST CHINA SCIENCE & TECH (CN) | 2009-11-18 | — | — | CN | claimed |
| US-20080051519-A1 | Polymers functionalized with nitro compounds | BRIDGESTONE CORPORATION (JP) | 2008-02-28 | — | — | US | claimed |
| US-20080051552-A1 | Polymers functionalized with nitro compounds | BRIDGESTONE CORPORATION | 2008-02-28 | — | — | US | claimed |
| EP-3972649-B1 | MCL-1 INHIBITOR ANTIBODY-DRUG CONJUGATES AND METHODS OF USE | NOVARTIS AG (CH) | 2026-05-13 | — | — | EP | disclosed |
| US-20260061065-A1 | ANTIBODY DRUG CONJUGATES | NOVARTIS AG (CH) | 2026-03-05 | — | — | US | disclosed |
| US-20250387504-A1 | ANTIBODY-DRUG CONJUGATES OF ANTINEOPLASTIC COMPOUNDS AND METHODS OF USE THEREOF | NOVARTIS AG (CH) | 2025-12-25 | — | — | US | disclosed |
| US-20250339547-A1 | MET BCL-XL INHIBITOR ANTIBODY-DRUG CONJUGATES AND METHODS OF USE THEREOF | NOVARTIS AG (CH) | 2025-11-06 | — | — | US | disclosed |
| WO-2024235134-A9 | CONJUGATE HAVING TARGETING EFFECT, AND PREPARATION METHOD THEREFOR AND USE THEREOF | 四川科伦博泰生物医药股份有限公司 | 2025-06-19 | — | — | WO | disclosed |
| WO-2024235136-A9 | HETEROCYCLIC COMPOUND, AND PREPARATION METHOD THEREFOR AND USE THEREOF | 四川科伦博泰生物医药股份有限公司 | 2025-06-19 | — | — | WO | disclosed |
| US-4220357-A | PRESSURE SENSITIVE OR HEAT SENSITIVE SYSTEMS | STERLING DRUG INC. (US) | 1980-09-02 | — | — | US | disclosed |
| US-4209618-A | COLOR PRECURSORS IN PRESSURE-SENSITIVE DUPLICATING SYSTEMS AND HEAT-SENSITIVE MARKING SYSTEMS | STERLING DRUG INC. (US) | 1980-06-24 | — | — | US | disclosed |
| US-4096176-A | Benzoylbenzoic acids | STERLING DRUG INC. (US) | 1978-06-20 | — | — | US | disclosed |
| US-4094877-A | SUBSTITUTED 3,3-DIPHENYLPHTHALIDES AS COLOR PRECURSORS | STERLING DRUG INC. (US) | 1978-06-13 | — | — | US | disclosed |
| US-4032527-A | COLOR PRECURSORS | STERLING DRUG INC. (US) | 1977-06-28 | — | — | US | disclosed |
| US-3959269-A | TRANQUILIZERS, SEDATIVES | SANDOZ, INC. (US) | 1976-05-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250387504-A1 | ANTIBODY-DRUG CONJUGATES OF ANTINEOPLASTIC COMPOUNDS AND METHODS OF USE THEREOF | BID, BCL2, MCL1 | ALDH1A1 4315/4885PTPRC 852/4885S100A4 2545/4885 |
| US-20250339547-A1 | MET BCL-XL INHIBITOR ANTIBODY-DRUG CONJUGATES AND METHODS OF USE THEREOF | MET, BCL3, BCL9 | ALDH1A1 2347/4885PTPRC 106/4885S100A4 2927/4885 |
| US-20260061065-A1 | ANTIBODY DRUG CONJUGATES | FCGR2A, FCGR3B, BCL3 | ALDH1A1 3069/4885PTPRC 1415/4885S100A4 4090/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.